An RCT of cannabinoid replacement therapy (Sativex®) for the management of treatment-resistant cannabis dependent patients

点击翻译按钮获取中文摘要

This project is the first-ever outpatient RCT to test if the pharmaceutical cannabinoid Sativex can safely and cost-effectively deliver better treatment outcomes for patients seeking treatment for chronic cannabis dependence. Sativex is a mouth spray with equal parts THC and cannabidiol, and appears to have a safer pharmacological profile than illicit cannabis or synthetic THC alone. Thus Sativex may lead to lower rates of psychiatric adverse events and increased cannabis abstinence rates.